Cyclerion Therapeutics Inc Financials
Cyclerion Therapeutics Inc (CYCN) reported $2.1M in revenue for fiscal year 2025, up 3.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Tiny revenue, expense cuts, and outside financing are the main forces keeping Cyclerion's cash position stable.
In FY2025,$3.3M of financing inflow almost matched-$3.3M of operating cash flow. That is why cash still ended the year near$3.2M : with revenue only$2.1M , the steady cash balance was created by capital raising, not by internally generated cash.
The business has been downsized to reduce burn: over the last two annual periods, SG&A plus R&D fell by about
Liquidity looks comfortable in the short term: a 5.2x current ratio and just
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Cyclerion Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Cyclerion Therapeutics Inc scores -26.13, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($19.3M) relative to total liabilities ($900K). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Cyclerion Therapeutics Inc passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
Cyclerion Therapeutics Inc reported a net loss of $3.5M while operations used $3.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Cyclerion Therapeutics Inc generated $2.1M in revenue in fiscal year 2025. This represents an increase of 3.7% from the prior year.
Cyclerion Therapeutics Inc reported -$3.5M in net income in fiscal year 2025. This represents a decrease of 15.4% from the prior year.
Cyclerion Therapeutics Inc earned -$1.11 per diluted share (EPS) in fiscal year 2025. This represents an increase of 8.3% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Cyclerion Therapeutics Inc held $3.2M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Cyclerion Therapeutics Inc's ROE was -38.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 4.3 percentage points from the prior year.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Cyclerion Therapeutics Inc invested $959K in research and development in fiscal year 2025. This represents an increase of 235.3% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
CYCN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $2.1M+3.7% | $2.0M | $0-100.0% | $297K-92.5% | $3.9M+71.7% | $2.3M-49.1% | $4.5M | N/A |
| R&D Expenses | N/A | $959K+235.3% | $286K-81.1% | $1.5M-74.7% | $6.0M-84.1% | $37.6M-33.3% | $56.4M-40.7% | $95.1M | N/A |
| SG&A Expenses | $7.1M | $6.1M+14.0% | $5.3M-34.3% | $8.1M-36.8% | $12.9M-37.6% | $20.6M-28.4% | $28.8M-16.2% | $34.4M+24.9% | $27.5M |
| Operating Income | -$6.8M | -$5.0M-37.1% | -$3.6M+72.0% | -$13.0M+30.1% | -$18.5M+66.4% | -$55.2M+32.1% | -$81.3M+35.0% | -$125.0M | N/A |
| Income Tax | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$6.7M | -$3.5M-15.4% | -$3.1M+41.9% | -$5.3M+88.1% | -$44.1M+14.7% | -$51.6M+33.6% | -$77.8M+36.8% | -$123.0M | N/A |
| EPS (Diluted) | — | -$1.11+8.3% | -$1.21+46.2% | -$2.25+88.9% | -$20.28 | -$1.32 | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CYCN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $10.0M+4.3% | $9.6M-28.4% | $13.4M-26.0% | $18.1M-69.5% | $59.3M-48.6% | $115.4M-38.1% | $186.5M+2419.6% | $7.4M |
| Current Assets | $4.6M+9.7% | $4.2M-47.3% | $8.0M-45.9% | $14.8M-73.3% | $55.5M-5.2% | $58.5M-42.2% | $101.2M+11412.7% | $879K |
| Cash & Equivalents | $3.2M+0.2% | $3.2M-57.3% | $7.6M-43.4% | $13.4M-75.2% | $54.0M-0.8% | $54.4M-42.7% | $94.9M | $0 |
| Accounts Receivable | $1.0M+79.9% | $556K | $0-100.0% | $96K-4.0% | $100K | $0 | N/A | N/A |
| Total Liabilities | $900K+24.1% | $725K-65.2% | $2.1M-72.6% | $7.6M-31.2% | $11.1M-80.2% | $55.9M-37.0% | $88.7M+397.3% | $17.8M |
| Current Liabilities | $900K+24.1% | $725K-65.2% | $2.1M-72.6% | $7.6M-31.2% | $11.1M-34.6% | $17.0M-7.1% | $18.2M+2.3% | $17.8M |
| Total Equity | $9.1M+2.7% | $8.8M-21.6% | $11.3M+8.0% | $10.5M-78.3% | $48.2M-18.9% | $59.5M-39.1% | $97.7M+1035.7% | -$10.4M |
| Retained Earnings | -$271.0M-1.3% | -$267.5M-1.2% | -$264.4M-2.0% | -$259.2M-20.5% | -$215.1M-31.6% | -$163.4M-90.9% | -$85.6M | N/A |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
CYCN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.5M | -$3.3M+23.5% | -$4.3M+79.6% | -$21.2M+47.7% | -$40.6M-11.2% | -$36.5M+49.6% | -$72.5M+29.1% | -$102.2M | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A | $0-100.0% | $7K-99.5% | $1.5M-77.9% | $6.9M+100.3% | $3.4M |
| Free Cash Flow | N/A | N/A | N/A | N/A | -$40.6M-11.2% | -$36.5M+50.7% | -$74.0M+32.2% | -$109.1M | N/A |
| Investing Cash Flow | N/A | N/A | $0-100.0% | $10.4M | $0-100.0% | $1.5M+7994.4% | $18K+100.3% | -$6.7M-95.3% | -$3.4M |
| Financing Cash Flow | $2.9M | $3.3M | $0-100.0% | $5.0M+17224.1% | $29K-99.9% | $30.8M+9.6% | $28.1M-86.7% | $211.6M | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CYCN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -239.8% | -181.4% | N/A | -6242.4% | -1400.2% | -3539.4% | -2774.3% | N/A |
| Net Margin | -170.1% | -152.8% | N/A | -14841.1% | -1310.2% | -3388.6% | -2729.3% | N/A |
| Return on Equity | -38.8%-4.3pp | -34.5%+12.1pp | -46.6%+375.1pp | -421.7%-314.7pp | -107.0%+23.7pp | -130.8%-4.9pp | -125.9% | N/A |
| Return on Assets | -35.3%-3.4pp | -31.9%+7.4pp | -39.4%+204.5pp | -243.8%-156.8pp | -87.1%-19.6pp | -67.4%-1.5pp | -66.0% | N/A |
| Current Ratio | 5.15-0.7x | 5.83+2.0x | 3.85+1.9x | 1.94-3.1x | 5.00+1.6x | 3.45-2.1x | 5.55+5.5x | 0.05 |
| Debt-to-Equity | 0.100.0x | 0.08-0.1x | 0.18-0.5x | 0.73+0.5x | 0.23-0.7x | 0.940.0x | 0.91 | N/A |
| FCF Margin | N/A | N/A | N/A | -13673.7% | -926.5% | -3223.6% | -2420.8% | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Cyclerion Therapeutics Inc Ranks
Frequently Asked Questions
What is Cyclerion Therapeutics Inc's annual revenue?
Cyclerion Therapeutics Inc (CYCN) reported $2.1M in total revenue for fiscal year 2025. This represents a 3.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cyclerion Therapeutics Inc's revenue growing?
Cyclerion Therapeutics Inc (CYCN) revenue grew by 3.7% year-over-year, from $2.0M to $2.1M in fiscal year 2025.
Is Cyclerion Therapeutics Inc profitable?
No, Cyclerion Therapeutics Inc (CYCN) reported a net income of -$3.5M in fiscal year 2025.
What is Cyclerion Therapeutics Inc's return on equity (ROE)?
Cyclerion Therapeutics Inc (CYCN) has a return on equity of -38.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Cyclerion Therapeutics Inc's operating cash flow?
Cyclerion Therapeutics Inc (CYCN) recorded an outflow of $3.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Cyclerion Therapeutics Inc's total assets?
Cyclerion Therapeutics Inc (CYCN) had $10.0M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Cyclerion Therapeutics Inc spend on research and development?
Cyclerion Therapeutics Inc (CYCN) invested $959K in research and development during fiscal year 2025.
What is Cyclerion Therapeutics Inc's current ratio?
Cyclerion Therapeutics Inc (CYCN) had a current ratio of 5.15 as of fiscal year 2025, which is generally considered healthy.
What is Cyclerion Therapeutics Inc's debt-to-equity ratio?
Cyclerion Therapeutics Inc (CYCN) had a debt-to-equity ratio of 0.10 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cyclerion Therapeutics Inc's return on assets (ROA)?
Cyclerion Therapeutics Inc (CYCN) had a return on assets of -35.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Cyclerion Therapeutics Inc's cash runway?
Based on fiscal year 2025 data, Cyclerion Therapeutics Inc (CYCN) had $3.2M in cash against an annual operating cash burn of $3.3M. This gives an estimated cash runway of approximately 12 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Cyclerion Therapeutics Inc's Altman Z-Score?
Cyclerion Therapeutics Inc (CYCN) has an Altman Z-Score of -26.13, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Cyclerion Therapeutics Inc's Piotroski F-Score?
Cyclerion Therapeutics Inc (CYCN) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cyclerion Therapeutics Inc's earnings high quality?
Cyclerion Therapeutics Inc (CYCN) reported a net loss of $3.5M while operations used $3.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Cyclerion Therapeutics Inc?
Cyclerion Therapeutics Inc (CYCN) scores 63 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.